View Clinical Trial (Medical Research Study)

Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma - NCT00733824-63110(Clinical Trial 235901)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  St. Louis
State:  
MO
Zip Code: 63110
Conditions: Lymphoma, Non-Hodgkin - Hodgkin Disease
Purpose: This study will evaluate the safety and efficacy of intravenous AMD3100 added to a standard G-CSF mobilization regimen of patients undergoing autologous stem cell transplantation for lymphoma. We hypothesize that after stem cell mobilization with G-CSF plus IV AMD3100, a significantly higher proportion of lymphoma patients will collect ≥ 2 x 10E6 CD34+ cells/kg.
Study summary: Autologous stem cell transplantation (ASCT) is indicated for patients with non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) who have primary progressive disease or who relapse after a chemotherapy-induced complete remission. For these patients, as for other patients undergoing autologous transplantation, the number of CD34+ cells collected is a reliable predictor of neutrophil and platelet (PLT) engraftment after transplantation. AMD3100 (plerixafor) is a promising new mobilizing agent that has demonstrated efficacy in patients with NHL, HL, and multiple myeloma (MM). Although efficacious, the subcutaneous dosing of AMD3100 requires that patients receive the drug in the evening prior to apheresis, which can present logistical problems. Intravenous dosing of AMD3100 may result in a faster rise in peripheral CD34+ cell count, so that the drug can be administered the same day as apheresis. Intravenous dosing may also increase the peak CD34+ cell count, improving the number of CD34+ cells collected via apheresis. This Phase I/II study will evaluate the safety and efficacy of intravenous AMD3100 added to the standard G-CSF mobilization regimen of patients undergoing autologous stem cell transplantation for Hodgkin and non-Hodgkin lymphomas.
Criteria: Inclusion Criteria: - Age 18 to 75 years - Diagnosis of HL or NHL eligible for autologous transplantation - 30 days since last cycle of chemotherapy - ECOG performance status of 0 or 1 - The patient has recovered from all acute toxic effects of prior chemotherapy - WBC >3.0 X 109/l - Absolute PMN count >1.5 X 109/l - PLT count >100 X 109/l - Serum creatinine ≤ 2.2 mg/dl - AST (SGOT), ALT (SGPT) and total bilirubin < 2X upper limit of normal (ULN) - Left ventricle ejection fraction > 45% (by ECHO or MUGA scan) - FEV1 > 60% of predicted or DLCO > 45% of predicted - Negative for HIV on standard transplant workup - Signed informed consent - Women of child bearing potential must agree to use an approved form of contraception Exclusion Criteria: - A co-morbid condition which, in the view of the investigator, renders the patient at high risk for treatment complications - Patients who have failed previous collections - A residual acute medical condition resulting from prior chemotherapy - Acute infection - Fever (temp >38C/100.4F) on the day of start of treatment - Positive pregnancy test in female patients - Lactating females - Patients of child bearing potential unwilling to implement adequate birth control - Patients whose actual body weight exceeds 150% of their ideal body weight - History of ventricular arrhythmias - Patients who previously received experimental therapy within 4 weeks of enrolling in this study or who are currently enrolled in another experimental study during the mobilization phase - Patients who have deterioration of their clinical status or laboratory parameters between the time of enrollment and transplantation such that they no longer meet entry criteria may be removed from study at the discretion of the treating physician, principal investigator, or sponsor
Study is available at: Washington University
St. Louis, MO 63110
United States

Primary Contact:
Amanda Cashen, M.D.
Email: acashen@dom.wustl.edu
Phone: 314-454-8304

Secondary Contact:
Amanda F. Cashen, M.D.
Email: acashen@dom.wustl.edu
Phone: 314-454-8304
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.